Navigation Links
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Date:2/21/2012

13 potentially resulting in key human pharmacokinetic data validating Xtend technology.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such as Amgen, Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For more information, please visit www.xencor.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
4. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
5. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
7. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
8. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
9. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
10. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
11. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... STEPh, Inc., a full service medical communications ... web site ( http://www.stephreports.com ) dedicated to ... STEPh Reports STEPh Reports are comprehensive critical ... STEPh Report assesses the competitive landscape by individual drug ... and specific key issues.  STEPh Reports are written by ...
(Date:5/22/2013)... Minn. , May 22, 2013 /PRNewswire/ ... the successful completion of its global Phase ... an internally developed program for the management ... proprietary formulation technology.  USL255 is specifically engineered ... fluctuations in topiramate blood levels observed with ...
(Date:5/22/2013)... 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would ... some recent company developments. As Medifirst continues to expand ... with shareholders. Integrating social media into its investor relations ... will post updates on Twitter.  The Facebook homepage is ... Says CEO Bruce J. Schoengood ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Medifirst Solutions, Inc. Announces Update To Shareholders 2
... 60,000 young children end up in emergency rooms every ... caregivers were not looking. To remind parents and caregivers ... for Disease Control and Prevention (CDC) and the Consumer ... the PROTECT Initiative , today launched the ...
... Dec. 13 , 2011 Mirixa Corporation, the leader ... that Stacey Lelko has joined the company as Vice ... lead Mirixa,s national sales team and develop strategic partner ... Ms. Lelko most recently served as Vice President ...
Cached Medicine Technology:CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 2CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 3Mirixa Names New VP of Sales and Business Development 2
(Date:5/22/2013)... By Amy Norton HealthDay Reporter , , WEDNESDAY, ... wrestled with athlete,s foot knows there is something about ... have the first detailed "map" of the fungal groups ... feet are the hottest neighborhood. It,s no ... organisms, such as bacteria, viruses and fungi, both outside ...
(Date:5/22/2013)... May 22, 2013 Successful Therapy ... Patricia O’Laughlin Psychotherapy in the Silver Lake community ... all ages as progression to existing Parents and ... ages into parenting therapy has always been suggested, ... O’Laughlin Psychotherapy now specializes in all aspects of ...
(Date:5/22/2013)... According to a May 14, 2013 US News ... Breast Cancer Surgery,” modern medical technology has given women with ... in a whole new light. Since the new approach known ... breast cancer and mastectomies with greater hope for a ... of plastic surgery to oncology, women had little choice but ...
(Date:5/22/2013)... disparities from the University of Miami Miller School of ... teamed up to hold the second annual "Why We ... Medicine." The theme of this year,s conference will ... reduce these disparities. , Despite steady improvement in the ... groups continue to be more vulnerable to lapses in ...
(Date:5/22/2013)... Award Presented at the 2013 Annual ... here: http://bit.ly/13DkFfk , Merrill Corporation is pleased ... Product/Service of the Year” at the 7th M&A Advisor ... Hotel in Palm Beach, Florida. , Merrill DataSite ... solution that optimizes the due diligence process and ...
Breaking Medicine News(10 mins):Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3
... submitted by Age Concern and London School of Hygiene and ... years are having an increased threat for disease due to ... that old age people are not spending the required amount ... eye care costs and are not undergoing the recommended 30 ...
... and doctors, and increases medical error risks, according to ... heating and cooling systems and by loud voices of ... short-term memory, according to the study by Johns Hopkins ... two-year research project, acoustics experts Ilene Busch-Vishniac and James ...
... that more lizard families than assumed till now are ... , The researchers, writing in the journal Nature ... like pain and swelling from lizard bites, which were ... of meat left between their teeth from their scavenging ...
... diabetes as a strong risk factor for sudden cardiac ... the disease.// ,The authors writing in the October ... prevalence of diabetes mellitus in industrialized countries is rapidly ... high risk for sudden cardiac death. ,The ...
... organisms, are exposed to ever-changing environments, oxidative stress, ... to defend themselves against all these insults, gain ... simply by ‘stealing’ genetic information from other better-adapted ... sex, known as horizontal gene transfer. ...
... A dengue fever vaccine full of promise is being tried ... of the GlaxoSmithKline vaccine //have been completed in the US ... be finished by the end of next year, Dr. Hans ... strong interest in making the vaccine available fast, given that ...
Cached Medicine News:Health News:More Lizards, Including Pets, Found Venomous 2Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: